About Endoplasmic reticulum-Golgi intermediate compartment protein 1
Endoplasmic reticulum-Golgi intermediate compartment protein 1 (ERGIC1) is a protein
from Homo sapiens identified by UniProt accession
Q969X5, 290 residues long.
MolForge cross-references it against 0 known binders and
39 disease associations.
Target properties
| Protein name | Endoplasmic reticulum-Golgi intermediate compartment protein 1 |
| UniProt accession | Q969X5 |
| Gene | ERGIC1 |
| Organism | Homo sapiens |
| Length | 290 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (39)
Diseases linked to this target (Open Targets).
- arthrogryposis multiplex congenita 2, neurogenic type · score 0.50
- Neurogenic arthrogryposis multiplex congenita · score 0.50
- Varicose veins · score 0.29
- Flexion contracture · score 0.26
- amyotrophic lateral sclerosis · score 0.21
- mean corpuscular hemoglobin concentration · score 0.18
- mean corpuscular volume · score 0.11
- whole body water mass · score 0.07
- lean body mass · score 0.06
- fat body mass · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q969X5-F1 | alphafold | PREDICTED | 89.04 | — |
Amino-acid sequence (290 residues)
MPFDFRRFDI YRKVPKDLTQ PTYTGAIISI CCCLFILFLF LSELTGFITT EVVNELYVDD PDKDSGGKID VSLNISLPNL HCELVGLDIQ DEMGRHEVGH IDNSMKIPLN NGAGCRFEGQ FSINKVPGNF HVSTHSATAQ PQNPDMTHVI HKLSFGDTLQ VQNIHGAFNA LGGADRLTSN PLASHDYILK IVPTVYEDKS GKQRYSYQYT VANKEYVAYS HTGRIIPAIW FRYDLSPITV KYTERRQPLY RFITTICAII GGTFTVAGIL DSCIFTASEA WKKIQLGKMH
Explore Endoplasmic reticulum-Golgi intermediate compartment protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets